SIRT1 and type 2 diabetes mellitus: Accumulating evidence suggests that SIRT1 and SIRT1 activators can prevent and reverse insulin resistance and diabetic complications, proven to be a promising therapeutic target in type 2 diabetes (T2D) [27–30].